PathoGenesis is Outward Bound
Executive SummaryPathoGenesis has begun life serving the niche market of cystic fibrosis. But the firm says this focused business model is just the launch point for expansion into other, larger chronic infectious respiratory markets.
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
The FDA has readied plans for hastened emergency-use approvals of coronavirus test kits after an infected US citizen returned to Washington State from Wuhan province in China. See what the FDA’s Megan McSeveney said about it here.